The mission of the Molecular Cytology Core is to deliver cutting-edge, specialized services in support of research projects at the Center. The methodologies employed by the Core allow for the detection in situ (in cells, tissue sections, organoids and whole mounts) of biomarkers (proteins, glycoproteins, lipids, nucleic acids) and molecular processess in normal and pathological conditions. The precise localization of the biomarkers is achieved by optical imaging of fixed and live samples. Several molecular markers (up to seven) can be vizualized simultanously or sequentially in the same sample by multiplex staining, using machine-based protocols. In collaboration with its users, the Core performs comprehensive antibody validations. The Core trains investigators in basic staining principles and assists them in performing manual experiments. The optical imaging modalities within the Core allow for wide field imaging and confocal imaging of tissue sections, thick and cleared tissue samples, cells, live embryos, tumors in live mice, etc. Super-resolution imaging is performed as well as confocal imaging in the IR range to visualize nanomaterials and drugs. With the newly acquired module for fluorescence correlation spectroscopy (FCS) imaging, researchers can study the dynamic behavior of biomolecules. The Core scans user slides with four digital slide scanners, one of which has confocal capabilities. The scanning generates large volumes of data and serves as a valuable resource for image analysis. Microscopy staff provides strong support for the users with 2D and 3D image analysis. The Core?s Atomic Force microscope is heavily used to study molecular interactions with nanometer resolution, to evaluate the effect of inhibitors on pathologic processes, and to assess stiffness of tissues from normal and cancer- bearing animals as well as tissues from cancer patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA008748-54
Application #
9858279
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2020-01-01
Budget End
2020-12-31
Support Year
54
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Kavaler, Joshua; Duan, Hong; Aradhya, Rajaguru et al. (2018) miRNA suppression of a Notch repressor directs non-neuronal fate in Drosophila mechanosensory organs. J Cell Biol 217:571-583
Bosse, Tjalling; Nout, Remi A; McAlpine, Jessica N et al. (2018) Molecular Classification of Grade 3 Endometrioid Endometrial Cancers Identifies Distinct Prognostic Subgroups. Am J Surg Pathol 42:561-568
Hellmann, Matthew D; Nathanson, Tavi; Rizvi, Hira et al. (2018) Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. Cancer Cell 33:843-852.e4
Scordo, Michael; Morjaria, Sejal M; Littmann, Eric R et al. (2018) Distinctive Infectious Complications in Patients with Central Nervous System Lymphoma Undergoing Thiotepa, Busulfan, and Cyclophosphamide-conditioned Autologous Stem Cell Transplantation. Biol Blood Marrow Transplant 24:1914-1919
Byron, Sara A; Tran, Nhan L; Halperin, Rebecca F et al. (2018) Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma. Clin Cancer Res 24:295-305
Zarnegar, Sara; Durham, Benjamin H; Khattar, Pallavi et al. (2018) Novel activating BRAF fusion identifies a recurrent alternative mechanism for ERK activation in pediatric Langerhans cell histiocytosis. Pediatr Blood Cancer 65:
Francis, Jasmine H; Slakter, Jason S; Abramson, David H et al. (2018) Treatment of juxtapapillary hemangioblastoma by intra-arterial (ophthalmic artery) chemotherapy with bevacizumab. Am J Ophthalmol Case Rep 11:49-51
Lee, Stanley Chun-Wei; North, Khrystyna; Kim, Eunhee et al. (2018) Synthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene Mutations. Cancer Cell 34:225-241.e8
Motzer, Robert J; Escudier, Bernard; Powles, Thomas et al. (2018) Long-term follow-up of overall survival for cabozantinib versus everolimus in advanced renal cell carcinoma. Br J Cancer 118:1176-1178
Giancipoli, Romina Grazia; Monti, Serena; Basturk, Olca et al. (2018) Complete metabolic response to therapy of hepatic epithelioid hemangioendothelioma evaluated with 18F-fluorodeoxyglucose positron emission tomography/contrast-enhanced computed tomography: A CARE case report. Medicine (Baltimore) 97:e12795

Showing the most recent 10 out of 8799 publications